Open in PodwiseOpen

Podcast cover

BiotechTV · News

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Episodes

Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants

On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress

BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round

Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials

State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on

Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today

AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers

Page 22

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise